In a single patient report, a subject with metastatic melanoma pretreated with ipilimumab, an anti-CTLA-4 checkpoint inhibitor, was vaccinated with IDO-silenced DCs transfected with mRNA for survivin or hTERT tumor antigens. This evidence concerns the gene BIRC5 and metastatic melanoma.